Astatine-211 (211At) has physical properties that make it one of the top candidates for use
as a radiation source for alpha particle-based radionuclide therapy, also referred as targeted …

Abstract Astatine-211 (211 At, t 1/2= 7.21 h) emitting two α particles with energies of 5.87
and 7.45 MeV, can lead to a high linear energy transfer (LET= 98.84 keV/µm) and short …

Eliminating microscopic residual disease with α-particle radiation is theoretically appealing.
After extensive preclinical work with α-particle–emitting 211At, we performed a phase I trial …

Introduction Antibodies labeled with alpha-emitter astatine-211 have previously shown
effective in intraperitoneal (ip) treatments of ovarian cancer. In the present work we explore …

We have developed the 16F12 mouse monoclonal antibody (mAb), which targets the
Müllerian-inhibiting substance receptor, type II (MISRII), expressed by ovarian tumors. Here …

Background In radiopharmaceutical therapies (RPT) involving beta emitters, absorbed dose
(Dabs) calculations often employ the use of dose voxel kernels (DVK). Such methods are …

This state-of-the-art handbook, the third and final in a series that provides medical physicists
with a comprehensive overview into the field of nuclear medicine, focuses on highlighting …

There have been many significant advances in the field of radioimmunotherapy since the
initial clinical studies were conducted in the 1980s. The emergence of monoclonal antibody …

Prostate cancer (PCa) is the most frequent cancer in men in the Western world.
Unfortunately, commonly available imaging modalities have not been shown to significantly …

Lymphoma has the characteristics of a solid tumor. Penetration of monoclonal antibodies is
limited in solid tumors during radioimmunotherapy (RIT). Here, we first investigated the use …